John Harry Cross III

Insider Reports History

Location
C/O Sonnet Biotherapeutics Holdings, Inc, 100 Overlook Center, Princeton, NJ
Signature
/s/ Robert Cutler, attorney-in-fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by John Harry Cross III:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Sonnet BioTherapeutics Holdings, Inc. Chief Financial Officer Common Stock 1.59K $1.68K $1.06 Dec 11, 2023 Direct
Senti Biosciences, Inc. Chief Financial Officer Stock Option (Right to Buy) 174K Mar 7, 2025 Direct

Insider Reports Filed by John Harry Cross III

Symbol Company Period Transactions Value $ Form Type Date Filed Role
SNTI Senti Biosciences, Inc. Mar 7, 2025 1 $0 4 Mar 11, 2025 Chief Financial Officer
SNTI Senti Biosciences, Inc. Mar 3, 2025 0 $0 3 Mar 11, 2025 Chief Financial Officer
SONN Sonnet BioTherapeutics Holdings, Inc. Dec 11, 2023 1 $0 4 Dec 5, 2024 Chief Financial Officer
SONN Sonnet BioTherapeutics Holdings, Inc. Feb 6, 2023 1 -$2.08K 4 Feb 17, 2023 Chief Financial Officer
SONN Sonnet BioTherapeutics Holdings, Inc. Dec 14, 2022 1 $0 4 Dec 22, 2022 Chief Financial Officer
SONN Sonnet BioTherapeutics Holdings, Inc. Dec 15, 2021 1 $0 4 Apr 8, 2022 Chief Financial Officer